{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CHANGE+Study&page=10",
    "query": {
      "intervention": "CHANGE Study",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 6732,
    "total_pages": 674,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CHANGE+Study&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CHANGE+Study&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T15:00:10.778Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06649812",
      "title": "Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type",
        "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type",
        "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
        "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements",
        "Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified",
        "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Obinutuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2025-10-07",
      "completion_date": "2028-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-10-24T15:00:10.778Z",
      "location_count": 114,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Derby, Connecticut + 93 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Derby",
          "state": "Connecticut"
        },
        {
          "city": "Guilford",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06649812"
    },
    {
      "nct_id": "NCT04538040",
      "title": "Bictegravir/Emtricitabine/Tenofovir Alafenide Plus Doravirine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "Bictegravir/emtricitabine/tenofovir alafenamide + Doravirine switch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Quest Clinical Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "45 Years and older · Male only"
      },
      "enrollment_count": 20,
      "start_date": "2019-12-19",
      "completion_date": "2021-11-11",
      "has_results": true,
      "last_update_posted_date": "2024-03-05",
      "last_synced_at": "2026-10-24T15:00:10.778Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04538040"
    },
    {
      "nct_id": "NCT05169489",
      "title": "A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diffuse Large B Cell Lymphoma (DLBCL)"
      ],
      "interventions": [
        {
          "name": "bbT369",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2022-01-24",
      "completion_date": "2025-09-19",
      "has_results": false,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-10-24T15:00:10.778Z",
      "location_count": 4,
      "location_summary": "Stanford, California • Denver, Colorado • Tampa, Florida + 1 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05169489"
    },
    {
      "nct_id": "NCT00586391",
      "title": "CD19 Chimeric Receptor Expressing T Lymphocytes In B-Cell Non Hodgkin's Lymphoma, ALL & CLL",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B Cell Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Acute Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "CD19CAR-28-zeta T cells",
          "type": "GENETIC"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 14,
      "start_date": "2009-02",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-24T15:00:10.778Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00586391"
    },
    {
      "nct_id": "NCT01736462",
      "title": "Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Corneal Endothelial Cell Changes"
      ],
      "interventions": [
        {
          "name": "Mapracorat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 61,
      "start_date": "2013-02",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2013-11-26",
      "last_synced_at": "2026-10-24T15:00:10.778Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01736462"
    },
    {
      "nct_id": "NCT06354088",
      "title": "Human Models of Selective Insulin Resistance: Alpelisib, Part I",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Insulin Resistance",
        "Prediabetic State",
        "Overweight and Obesity",
        "Non-Alcoholic Fatty Liver Disease"
      ],
      "interventions": [
        {
          "name": "Alpelisib 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "[1-13C] sodium acetate",
          "type": "DRUG"
        },
        {
          "name": "[6,6-2H2] D-glucose",
          "type": "DRUG"
        },
        {
          "name": "Mixed Meal Tolerance Test",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Nestlé BOOST Plus",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Columbia University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 32,
      "start_date": "2024-04-24",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-10-24T15:00:10.778Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06354088"
    },
    {
      "nct_id": "NCT02324361",
      "title": "Quincy Family, Youth & Technology For Lifestyle Change (FYT-4-LIFE) Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pediatric Obesity"
      ],
      "interventions": [
        {
          "name": "Physical Activity",
          "type": "OTHER"
        },
        {
          "name": "Evidence-based information on healthy family routines",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "7 Years",
        "sex": "ALL",
        "summary": "3 Years to 7 Years"
      },
      "enrollment_count": 48,
      "start_date": "2014-07",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2020-10-22",
      "last_synced_at": "2026-10-24T15:00:10.778Z",
      "location_count": 1,
      "location_summary": "Quincy, Massachusetts",
      "locations": [
        {
          "city": "Quincy",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02324361"
    },
    {
      "nct_id": "NCT01824797",
      "title": "Bone Metabolism After Bariatric Surgery",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Obesity",
        "Osteoporosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "40 Years and older · Female only"
      },
      "enrollment_count": 42,
      "start_date": "2013-05",
      "completion_date": "2018-05-31",
      "has_results": false,
      "last_update_posted_date": "2019-08-16",
      "last_synced_at": "2026-10-24T15:00:10.778Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01824797"
    },
    {
      "nct_id": "NCT00988624",
      "title": "A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease",
        "Huntington Disease"
      ],
      "interventions": [
        {
          "name": "Dimebon IR Tablet",
          "type": "DRUG"
        },
        {
          "name": "Dimebon MR1",
          "type": "DRUG"
        },
        {
          "name": "Dimebon MR2",
          "type": "DRUG"
        },
        {
          "name": "Dimebon MR3",
          "type": "DRUG"
        },
        {
          "name": "Dimebon MR4",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 20,
      "start_date": "2009-10",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2010-01-12",
      "last_synced_at": "2026-10-24T15:00:10.778Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00988624"
    },
    {
      "nct_id": "NCT05579470",
      "title": "Expanding Medication-Assisted Therapies in Central Asia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "NIATx",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 900,
      "start_date": "2023-08-07",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-14",
      "last_synced_at": "2026-10-24T15:00:10.778Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05579470"
    }
  ]
}